Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient.
暂无分享，去创建一个
G. Rao | Rajnikant Sharma | C. Ruh | Rashmi Banjade | D. Jacobs | J. Claus | Sara DiTursi
[1] R. Bonomo,et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? , 2016, Expert opinion on pharmacotherapy.
[2] Jianzhong Shen,et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. , 2015, The Lancet. Infectious diseases.
[3] R. Humphries,et al. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate , 2015, Antimicrobial Agents and Chemotherapy.
[4] Hui Wang,et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. , 2013, The Lancet. Infectious diseases.
[5] R. Widen,et al. Rapid detection of carbapenemase genes by multiplex real-time PCR. , 2012, The Journal of antimicrobial chemotherapy.